Skip to Content

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide which include:

Moderate

elvitegravir food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Food enhances the oral bioavailabilities of both elvitegravir and tenofovir. When a single dose of cobicistat/elvitegravir/emtricitabine/tenofovir (trade name Stribild) was given with a light meal (approximately 373 kcal; 20% fat), mean elvitegravir and tenofovir systemic exposures (AUCs) increased by 34% and 24%, respectively, relative to fasting conditions. When administered with a high-fat meal (approximately 800 kcal; 50% fat), the mean AUC of elvitegravir and tenofovir increased by 87% and 23%, respectively, relative to fasting conditions. The alterations in mean AUCs of cobicistat and emtricitabine were not clinically significant with either the light or high-fat meal.

MANAGEMENT: Cobicistat/elvitegravir/emtricitabine/tenofovir as a fixed-dose preparation should be administered once daily with food. Elvitegravir as a single-ingredient preparation should also be administered once daily with food.

References

  1. "Product Information. Vitekta (elvitegravir)." Gilead Sciences, Foster City, CA.
  2. "Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov)." Gilead Sciences, Foster City, CA.
Minor

tenofovir food

Minor Food Interaction

Information for this minor interaction is available on the professional version.

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide drug interactions

There are 573 drug interactions with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide

Cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide disease interactions

There are 10 disease interactions with cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide which include:

More about cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.